NCT03809624 - Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

October 3, 2024

Study Completion Date

October 3, 2024

Conditions

Metastatic Solid TumorsNon-small Cell Lung CancerMelanomaHead and Neck Squamous Cell CarcinomaGastric AdenocarcinomaRenal Cell CarcinomaEsophageal AdenocarcinomaNasopharyngeal CarcinomaOropharyngeal Carcinoma

Interventions

DRUG

INBRX-105 - PDL1x41BB antibody

The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.

DRUG

Pembrolizumab

Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Trial Locations (23)

19104

Abramson Cancer Center - University of Pennsylvania, Philadelphia

Abramson Cancer Center at Pennsylvania Hospital, Philadelphia

22031

Virginia Cancer Specialists, Fairfax

30322

Emory University - Winship Cancer Institute, Atlanta

37204

Vanderbilt University Medical Center, Nashville

40202

Norton Cancer Center, Louisville

46526

Goshen Center for Cancer Care, Goshen

49546

START Midwest, Grand Rapids

63110

Washington University, St Louis

68114

Nebraska Cancer Specialists - Grand Island, Omaha

68130

Nebraska Cancer Specialists, Omaha

77030

MD Anderson Cancer Center, Houston

78229

New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio

80045

University of Colorado Denver, Denver

84119

START Mountain Region, West Valley City

85258

HonorHealth Research Institute, Scottsdale

90069

Valkyrie Clinical Trials, Los Angeles

91010

City of Hope at Irvine Lennar, Duarte

City of Hope, Duarte

94304

Stanford University, Palo Alto

97213

Providence Cancer Institute, Portland

98405

Northwest Medical Specialties, PLLC, Tacoma

02114

Massachusetts General Hospital, Boston